Emergent Biosolutions Inc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

EBS 35.91 -0.13 (-0.36%)
price chart
Stifel Financial Corp Has $379000 Stake in Emergent Biosolutions, Inc. (EBS)
Emergent Biosolutions logo Stifel Financial Corp boosted its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 50.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission.
Emergent Biosolutions Inc (NYSE:EBS) 2016 Q4 Sentiment Report  WeeklyHub
Emergent BioSolutions Inc. (EBS) registers a price change of -2.27% while ...  Stocks Gallery
Emergent BioSolutions to acquire anthrax treatment, move manufacturing to ...
Emergent BioSolutions, a Gaithersburg-based drug maker with facilities in Baltimore, has acquired a drug used to treat anthrax from GlaxoSmithKline in a deal worth up to $96 million.
Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million  Washington Business Journal
Emergent BioSolutions to Release Second Quarter 2017 Financial Results and ...  Nasdaq
Emergent Biosolutions Inc. Moves Things Around, Still Sees Growth
Emergent BioSolutions is also planning on running two trials for Trobigard, which will help it gain approval from the Food and Drug Administration so it can be sold to the U.S.
Emergent BioSolutions opens expanded East Baltimore vaccine plant  Baltimore Sun
Emergent BioSolutions Inc Sets Its Goal
Emergent BioSolutions (NYSE:EBS) released fourth-quarter earnings on Thursday. The company announced preliminary numbers in January so it could talk about the results at the JP Morgan Healthcare conference, but the actual numbers were slightly better ...
Emergent BioSolutions: A Very Attractive Risk/Reward Biodefense Play
In the aftermath of the anthrax attacks of 2001, the swine flu pandemic of 2009, the Ebola outbreak of 2014, and the recent Zika scare, biodefense is more important than ever.
Emergent Biosolutions Inc (EBS) Shares Sold by Capstone Asset Management Co.  BNB Daily (blog)
Emergent BioSolutions gets $100 million anthrax contract from feds
Gaithersburg-based Emergent BioSolutions Inc. won another lucrative anthrax contract from the feds, this time totaling $100 million over two years.
Why Emergent Biosolutions Inc. Stockpiled a Higher Price Today
Emergent BioSolutions (NYSE:EBS) is up 19.5% at 3:02 p.m. EST, after announcing a new contract with the Centers for Disease Control and Prevention (CDC) and a separate deal with the Biomedical Advanced Research and Development Authority ...
US federal agencies pledge up to $1.1B for Emergent Biosolutions' ...  BioWorld Online
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
Emergent BioSolutions Inc. (EBS - Free Report) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY - Free Report) in an all-cash deal of up to $125 million.
Emergent Biosolutions, Inc. (NYSE:EBS) Traded 6.9% Above Its 50 Day Moving ...  Highlight Press
Emergent Biosolutions Inc Slimmed Down, Waiting on Contract
The FDA signed off on Emergent BioSolutions' new larger manufacturing plant for BioThrax, dubbed Building 55. But it's still unknown how much product made in the new building will still be sold to the U.S.
Emergent Biosolutions to acquire Raxibacumab from GSK
Emergent Biosolutions Inc - emergent plans to assume responsibility for a multi-year contract with BARDA, valued at up to approximately $130 million.